Pharmaceutical

Travere signs $120m licensing deal with Renalys for sparsentan in Asia

Renalys plans to start a registrational trial for sparsentan as a treatment for IgA nephropathy in Japan in Q2 2024.

Jan 27, 2024 - 18:00
Travere signs $120m licensing deal with Renalys for sparsentan in Asia
Renalys plans to start a registrational trial for sparsentan as a treatment for IgA nephropathy in Japan in Q2 2024.
Read the original article

Tags:

Previous Article

FDA expands approval of Dupixent for eosinophilic esophagitis in children

Next Article

STAT+: From a small town in Wales, a scientific sleuth has shaken Dana-Farber — ...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

The Senate health committee looks into its first subpoena in 40 years

The Senate health committee looks into its first subpoe...

Jan 20, 2024

Critics and defenders weigh in on Stanford president’s resignation after research investigation

Critics and defenders weigh in on Stanford president’s ...

Jul 20, 2023

Teens seeking addiction care unlikely to be offered standard medication

Teens seeking addiction care unlikely to be offered sta...

Jun 14, 2023